HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Terbinafine versus itraconazole and fluconazole in the treatment of Vulvovaginal candidiasis.

Abstract
Vulvovaginal candidiasis is one of the most frequent infections of the female genital tract with a high incidence. Although numerous antimycotical agents are available for treatment of yeast vaginitis, there are few comparative data on the in vivo and in vitro activity of these drugs. The aim of this open, randomized, and comparative study was to determine in vivo and in vitro effectiveness of the 3 systemic antifungal agents: terbinafine and 2 azoles (itraconazole and fluconazole) in the treatment of patients with Vulvovaginal candidiasis. A total of 44 patients who had signs and symptoms of Vulvovaginal candidiasis were recruited for the study. Patients were randomly assigned to 3 groups: terbinafine 500 mg/d orally was used for 7 days, itraconazole 200 mg/d orally was used for 7 days, and fluconazole 150 mg orally was used as a single dose. Both clinical and mycologic examinations were performed for posttreatment assessment at week 4. This study revealed a clinical cure rate 33.3% for terbinafine, 60% for itraconazole, and 66.6% for fluconazole (P>0.05). Mycologic cure rates were 33.3%, 10%, and 66.6% respectively (P<0.05). Overall cure rates were 33.3%, 10%, and 53.3% (P>0.05). Terbinafine could be an alternative treatment option in Vulvovaginal candidiasis because there were no significant differences in the clinical and overall cure rates among 3 antifungal agents. However, terbinafine could not be suggested as a first-line treatment in Vulvovaginal candidiasis. Systemic use of terbinafine in larger numbers of cases may give more information about the effectiveness of this drug in the treatment of patients with vulvovaginal candidiasis.
AuthorsAyten Ferahbas, Ayse Nedret Koc, Umit Uksal, Ercan Aygen, Selcuk Mistik, Sinem Yildiz
JournalAmerican journal of therapeutics (Am J Ther) 2006 Jul-Aug Vol. 13 Issue 4 Pg. 332-6 ISSN: 1075-2765 [Print] United States
PMID16858169 (Publication Type: Comparative Study, Journal Article, Randomized Controlled Trial)
Chemical References
  • Antifungal Agents
  • Naphthalenes
  • Itraconazole
  • Fluconazole
  • Terbinafine
Topics
  • Adolescent
  • Adult
  • Antifungal Agents (therapeutic use)
  • Candidiasis, Vulvovaginal (drug therapy, microbiology)
  • Female
  • Fluconazole (therapeutic use)
  • Humans
  • Itraconazole (therapeutic use)
  • Male
  • Microbial Sensitivity Tests
  • Middle Aged
  • Naphthalenes (therapeutic use)
  • Terbinafine

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: